羟基氯喹
细胞激素风暴
氯喹
医学
2019年冠状病毒病(COVID-19)
药品
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
爆发
冠状病毒
抗病毒药物
病毒学
免疫学
疾病
疟疾
药理学
传染病(医学专业)
内科学
作者
Ripu Daman M. Singh,Nida Malim,Aves Ahmed Khan,Huda Khan,N. El Khatib,Aakifah Gounda
出处
期刊:Journal of Biomedical and Pharmaceutical Research
[CAB PUBLISHER]
日期:2020-06-05
卷期号:9 (3)
标识
DOI:10.32553/jbpr.v9i3.749
摘要
The coronavirus disease 19 (COVID-19) is a highly transmittable and pathogenic viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)bat viruses, therefore bats could be the possible primary reservoir , which emerged in Wuhan, China and spread around the world. The intermediate source of origin and transfer to humans is not known, however, the rapid human to human transfer has been confirmed widely. There is no clinically approved antiviral drug or vaccine available to be used against COVID-19. However, few broad-spectrum antiviral drugs have been evaluated against COVID-19 in clinical trials, resulted in clinical recovery. We also discuss the approaches for therapeutic combinations to cope with this viral outbreak.
Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI